The overall profile of Radiopharm Theranostics’ (ASX:RAD) pancreatic cancer imaging drug RAD 301 has this week been boosted by a published study.
The study by Dresden-based Dr. Jana Rehm, which ran in the ‘Frontiers in Nuclear Medicine’ journal, supported the use of RAD 301 (68Ga-Trivehexin) in imaging pancreatic cancers based on data the study used.
Titled “αvβ6-integrin targeted PET/CT imaging in pancreatic cancer patients using 68Ga-Trivehexin,” the paper noted RAD 301 detected 40 pancreatic cancers, with authors concluding “[suitability] for imaging of … pancreatic cancer due to its ability to distinguish primary carcinoma and metastases from background tissue.”
In the company’s words, a “high tumor-to-background ratio” was noted for RAD 301 when detecting cancers within the human pancreas.
Imaging agents, for the uninitiated, ultimately allow PET scan machines and similar methods to better identify dangerous growths in the human body. Patients are often injected, or told to take orally, solutions which enhance visualisations in those scans.
In the background, safety studies surrounding RAD 301 remain ongoing in New York.
“Current imaging standards of care for the detection of PDAC have significant limitations, making this one of the highest areas of unmet medical need and posing a major challenge for healthcare providers,” Radiopharm CEO Riccardo Canevari said.
“These findings reinforce the clinical potential of RAD 301 as an imaging agent for the more sensitive and selective detection.”
RAD last traded at 2.8cps.
Join the discussion: See what HotCopper users are saying about Radiopharm Theranostics and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.